Emerging research suggest Retatrutide , a dual agonist targeting both GLP-1 and another hormone, could offer a notable advancement for obesity treatment. Initial clinical investigations have shown considerable decreases in visceral tissue, potentially surpassing other weight-loss therapies . Nevertheless , further assessment is required to fully de